
    
      Eligible participants for this study must have a diagnosis of Neurodegenerative Disorder and
      must exhibit disinhibition syndrome of sufficient severity to warrant treatment.

      This is a multicenter, randomized, double-blind, placebo-controlled, cross-over study
      consisting of two 6-week treatment periods.

      Approximately 12 participants will be enrolled at approximately 2 centers in the United
      States.

      Following screening procedures for assessment of inclusion and exclusion criteria, eligible
      participants will be randomized into the study.
    
  